Table 2.
Adjusted changes from baseline in balance and participation outcomes
| Treatment Group | Endpoint | Estimate | SE | 95% CI | P Value | ES | |
|---|---|---|---|---|---|---|---|
| CB&M | |||||||
| VR | Wk 6 | 5.19 | 1.31 | (2.57-7.81) | .0002 | * | 0.29 |
| HEP | Wk 6 | 5.49 | 1.31 | (2.87-8.11) | <.0001 | * | 0.31 |
| VR – HEP | Wk 6 | −0.30 | 1.85 | (−4.01 to 3.40) | .8716 | 0.02 | |
| VR | Wk 12 | 7.73 | 1.66 | (4.41-11.05) | <.0001 | * | 0.43 |
| HEP | Wk 12 | 7.87 | 1.66 | (4.55-11.19) | <.0001 | * | 0.44 |
| VR – HEP | Wk 12 | −0.14 | 2.35 | (−4.84 to 4.55) | .9522 | 0.01 | |
| VR | Wk 24 | 8.60 | 1.39 | (5.81-11.38) | <.0001 | * | 0.48 |
| HEP | Wk 24 | 8.73 | 1.37 | (5.99-11.48) | <.0001 | * | 0.49 |
| VR – HEP | Wk 24 | −0.14 | 1.95 | (−4.05 to 3.77) | .9438 | 0.01 | |
| ABC | |||||||
| VR | Wk 6 | 3.30 | 1.76 | (−0.23 to 6.82) | .0663 | 0.26 | |
| HEP | Wk 6 | 0.65 | 1.75 | (−2.86 to 4.16) | .7138 | 0.05 | |
| VR – HEP | Wk 6 | 2.65 | 2.49 | (−2.32 to 7.62) | .2910 | 0.21 | |
| VR | Wk 12 | 1.62 | 1.64 | (−1.66 to 4.90) | .3271 | 0.13 | |
| HEP | Wk 12 | 2.60 | 1.64 | (−0.67 to 5.88) | .1171 | 0.21 | |
| VR – HEP | Wk 12 | −0.98 | 2.32 | (−5.62 to 3.65) | .6723 | 0.08 | |
| VR | Wk 24 | 3.75 | 1.91 | (−0.08 to 7.57) | .0550 | 0.30 | |
| HEP | Wk 24 | 2.45 | 1.86 | (−1.28 to 6.18) | .1940 | 0.19 | |
| VR – HEP | Wk 24 | 1.30 | 2.67 | (−4.05 to 6.64) | .6292 | 0.10 | |
| BESTest | |||||||
| VR | Wk 6 | 3.90 | 1.31 | (1.28-6.52) | .0042 | * | 0.23 |
| HEP | Wk 6 | 3.89 | 1.31 | (1.27-6.51) | .0043 | * | 0.23 |
| VR – HEP | Wk 6 | 0.01 | 1.85 | (−3.70 to 3.71) | .9973 | 0.00 | |
| VR | Wk 12 | 5.27 | 1.69 | (1.89-8.65) | .0028 | * | 0.31 |
| HEP | Wk 12 | 5.36 | 1.69 | (1.99-8.74) | .0023 | * | 0.31 |
| VR – HEP | Wk 12 | −0.09 | 2.39 | (−4.87 to 4.68) | .9693 | 0.01 | |
| VR | Wk 24 | 6.80 | 1.44 | (3.92-9.68) | <.0001 | * | 0.40 |
| HEP | Wk 24 | 5.89 | 1.42 | (3.05-8.74) | .0001 | * | 0.34 |
| VR – HEP | Wk 24 | 0.91 | 2.02 | (−3.14 to 4.96) | .6558 | 0.05 | |
| PART-O Summary | |||||||
| VR | Wk 6 | 0.00 | 0.05 | (−0.11 to 0.10) | .9523 | 0.00 | |
| HEP | Wk 6 | 0.08 | 0.05 | (−0.03 to 0.19) | .1494 | 0.18 | |
| VR – HEP | Wk 6 | −0.08 | 0.08 | (−0.23 to 0.07) | .2867 | 0.18 | |
| VR | Wk 12 | 0.02 | 0.05 | (−0.09 to 0.13) | .7023 | 0.04 | |
| HEP | Wk 12 | 0.04 | 0.05 | (−0.07 to 0.14) | .4977 | 0.09 | |
| VR – HEP | Wk 12 | −0.02 | 0.08 | (−0.17 to 0.14) | .8341 | 0.04 | |
| VR | Wk 24 | 0.07 | 0.07 | (−0.08 to 0.21) | .3676 | 0.15 | |
| HEP | Wk 24 | 0.04 | 0.07 | (−0.11 to 0.18) | .6204 | 0.09 | |
| VR – HEP | Wk 24 | 0.03 | 0.10 | (−0.17 to 0.23) | .7645 | 0.07 |
NOTE. Statistically significant (α=0.0167) for comparison of changes between groups. Abbreviations: CI, confidence interval;ES, effect size;SE, standard error.
*
Statistically significant (α=0.05) for within-group changes.